Sponsored by Gilead
This study reviews the current availability of CGTs and estimates future numbers of therapies that are likely to come onto the market up to 2031. Understand the challenges the technology presents to various healthcare actors and explore a scorecard which examines how well prepared nine countries (Australia, Canada, France, Germany, Italy, Japan, Spain, UK and US) are for rolling out CGTs.
Impact and opportunity: the case for investing in women’s cancers in Asia Pacific
Sponsored by APAC Women's Cancer Coalition and Roche
The burden of women’s cancer (specifically breast and cervical cancer) is examined in six countries in the APAC region: India, Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Using a benchmarking scorecard, thise research examines and compares the quality of policies and programmes to tackle cancer based on recommendations set by the World Health Organisation (WHO).
Rising to the metastatic breast cancer (MBC) challenge: current and future policy responses
Sponsored by Sanofi
This report highlights the diversity of challenges that people with MBC face around the world. It further identifies priorities for policymakers, advocacy organisations, health system administrators and other key stakeholders to improve the quality of life for individuals with MBC.